EIF1B

Across TCGA pan-cancer cohorts, EIF1B mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of EIF1B’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where EIF1B mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types EIF1B is over-expressed in tumor, although a few such as CCRCC and LSCC show the opposite, repressed pattern.

CCRCC, LSCC, and OV are the cancer types where EIF1B tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in EIF1B mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	All	−0.658	<.001	12	view →
LSCC	Female	All	−0.482	<.001	9	view →
OV	All	All	+0.988	.009	2	view →
LUAD	Female	All	−0.110	.041	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

EIF1B–CCRCC

Open the CCRCC breakdown →